Owner of cough syrup firm linked to 19 deaths held

Published
0
Nilesh Suryavanshi, 32, the father of a three year old child who has been admitted at the Government Medical College, holds a bottle of Coldrif cough syrup, which has been linked to the deaths of 17 children, in Nagpur, India on October 8, 2025. — Reuters
Nilesh Suryavanshi, 32, the father of a three year old child who has been admitted at the Government Medical College, holds a bottle of Coldrif cough syrup, which has been linked to the deaths of 17 children, in Nagpur, India on October 8, 2025. — Reuters

CHHINDWARA: Indian police have arrested the owner of Sresan Pharm­aceutical Manu­facturer, the cough syrup company linked to the deaths of 19 children in Madhya Pradesh.

The children, all under five years of age, died in the past month in the state’s Chhindwara city, after consuming cough medicine containing toxic diethylene glycol in quantities nearly 500 times the permissible limit.

The deaths were all linked to Sresan Pharma’s Coldrif syrup, which has been banned in several parts of India after a test confirmed the presence of the chemical last Thursday.

S. Ranganathan, owner of the Tamil Nadu state-based company that ­manufactured the syrup, was arrested on Wednesday in Chennai where he will appear in court before being moved to Chhi­ndwara, a police official said.

Local drug authorities have stepped up efforts to curb the circulation of contaminated medicine, testing random samples of cough syrups and making door-to-door calls to retrieve Coldrif bottles. “We (have) got 30-40 bottles (through this means)…we (also) recalled some from retailers and stockists,” district administrator Harendra Narayan said, adding that 594 bottles of the syrup were sold to pharmaceutical stockists in the region over the last six weeks.

By law, Indian drugmakers must test each batch of raw materials and the final product.

Exports of cough syrup require another layer of tests at government-mandated laboratories since 2023, after the deaths of over 10 children in Gambia, Uzbekistan and Cameroon were linked to Indian syrups.

The World Health Organisation has said the recent case highlights a “regulatory gap” in India’s screening of medicines and warned that some exports could have been made unofficially.

Published in Dawn, October 10th, 2025

Opinion

Editorial

Expanding conflict
31 Jul, 2026

Expanding conflict

WITH neither of the belligerents willing to back down, and the theatre of conflict expanding geographically, the...
Spoils and spats
31 Jul, 2026

Spoils and spats

A FIGHT over assembly seats in Azad Jammu and Kashmir has laid bare what seem to be some deep resentments between ...
Unfair tax system
31 Jul, 2026

Unfair tax system

THE disclosure that the FBR collected nearly Rs1.9tr in sales and income taxes through electricity bills over the...
Debt that stays
30 Jul, 2026

Debt that stays

THE power sector’s circular debt grew by Rs61bn in the last fiscal year, taking the total to roughly Rs1.67tr from...
HIV warning
30 Jul, 2026

HIV warning

THE HIV infections detected around two SESSI-run hospitals in Karachi demand far more than another hurried committee...
End trafficking
30 Jul, 2026

End trafficking

MODERN slavery, in the form of human trafficking, is among the state’s gravest failures. Scores of Pakistanis are...